

DAFTAR PUSTAKA

- Acharya M, Joshi PR, Thapa K, *et al.* (2017). Detectiob of metallo- β -lactamases-encoding genes among clinical isolats of *P. aeruginosa* in a tertiary care hospital, Kathmandu, Nepal. *BMC research notes* 10: 1-5.
- Agrawal *et al.*, (2008). Study Of Metallo-Beta-Lactamase Productions In Clinical Isolat Of *P. aeruginosa*. *Idian Journal Of Medical Microbiology*, 26 (4):349-51.
- Ahmed O.B., Asghar A.H., Bahwert F.S. (2015). Prevalence of ESBL Genes of *P. aeruginosa* Strains Isolatd from Makkah Hospitals, Saudi Arabia. *Erupian Journal of Biology and Medical Science Reserch*. Vo.3, No.6.p 1-7.
- Akinci E, Vahaboglu H. (2010). Minor extended-spectrum β -lactamases. *Expert review of anti-infective therapy* 10: 1251-8.
- Antunes NT, Fisher JF. (2014). Acquired class D β -Lactamases. *Antibiotics* 3: 398-434.
- Bahar MA, Jamali S, Samadikuchaksaraei A. (2010). Imipenem-resistant *P. aeruginosa* strains carry metallo-beta-lactamse gene bla(VIM) in a level I Iranian burn Hospital.
- Brend A. *et al.*, (2011). How Bacteria Becaome Esistans to Antibiotics, *Bacterial Pathogenesis A Molecular Approach*, (347-367).
- Brusselares N, Vogelaers D, Blot S. (2011). The rising problem of antimicrobial resistance in the intensive care unit. *Annals of intensive care* 1: 1-7.
- Budianto BR. (2016). Polymerase Chain Reaction (PCR) Perkembangan dan Perannya Dalam Diagnostik Kesehatan. *Biotrends* 6: 29-38.
- Chen Z, Niu H., Chen G., Li M., Li M., Zhou Y. (2015). Prevalence of ESBL . producing *Pseudomonas aeruginosa* Isolat from Different Wards in a Chinese Teaching Hospital. *Int J Clin Exp Med* 2015;8(10):19400-19405.
- Croughs P.D., Klassen C.H.W., Rosmale J., Maghdid D.M., Boers S.A., Hays J.P., Goessens W.H.F. (2018). Unexpected Mechanisms of Resistance in Ducth *P. aeruginosa* Isolats Collected During Fourteen Years of Surveillance. *Journal of Antimicrobial Agents*. Doi: 10.1016/j.ijntimicag.2018.05.009.

- Davodian E., Sadeghifard N., Ghasemian A., and Noorbakhsh S. 2015. Molecular Detection of *bla*_{VEB-1} Beta-Lactamase Encoding Gene Among Extended Spectrum B-Lactamase Positive Wound Isolates of *P. aeruginosa*. *Arch Pediatr Infect Dis*.
- De Matos ECO, De Matos HJ, Concei
- Dharmayanti IGAMP, Sykrama DM. (2019). Karakteristik Bakteri *P. aeruginosa* dan Pola Kepekaannya Terhadap Antibiotik di Intensive Care Unit (ICU) RSUP Sanglah Pada Bulan November 2014- Januari 2015. *E-Jurnal Medika Udayana*.
- Diene SM, Rolain J-M. (2014). Carbapenemase genes and genetic platforms in Gram-negative bacilli: *Enterobacteriaceae*, *P. aeruginosa* and *Acinetobacter species*. *Clinical Microbiology and Infection* 20: 831-8
- Direux L, Brossier F, Sougakoff W, *et al.* (2008). Phenotypic detection of extended-spectrum β -Lactamase production in Enterobacteriaceae: review and bench guide. *Clinical Microbiology and Infection*. 14: 90-103.
- Dugassa J, Shukuri N. (2017). Review on antibiotic resistance and its mechanism of development. *Journal of Health, Medicine and Nursing* 1:1-17.
- Ellington MJ, Kistler J, Livermore DM, Woodford N. Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. *J Antimicrob Chemother*. 2007;59(2):321-322.doi:10.1093/jac/dkl481.
- El Zowalaty ME, Al Thani AA, Webster TJ, *et al.* (2015). *P. aeruginosa*: arsenal of resistance mechanism, decades of changing resistance profiles, and future antimicrobial therapies. *Future Microbiology* 10: 1683-706.
- Fallah F, Borhan RS, Hashemi A. (2013). Detection of *bla* (IMP) and *bla* (VIM) metallo-beta-lactamases genes among *P. aeruginosa* strains.
- Farshadzadeh Z., Khosravi A.D., Alvi S.M., Parhizgari N., Hoveizavi H. (2014). Spread of Extended-Spectrum β -Lactamase Genes of *bla*_{oxa-10}, *bla*_{ctx-M} in *P. aeruginosa* Strain Isolated from burn Patients. *Jbur*-4301; No.of Pages 6.
- Fujitani S., Moffett K.S., Yu, V.L. (2017) *P. aeruginosa*. *Infectious Disease & Antimicrobial Agents*. p.1-28.

- Gian M. R. *et al.*, (2000). Carbapenemase-Resistant *P. aeruginosa* With Acquired blaVIM Metallo- β -Lactamase Determinant. Italy; *Emerging Infectious Diseases*. Vol. 6 no 3 May-Jun.
- Gibbs RA. (1990). DNA amplification by the polymerase chain reaction. *Analytical chemistry* 62: 1202-14.
- González-Bello C. (2017). Antibiotic adjuvants-A strategy to unlock bacterial resistance to antibiotics. *Bioorganic & medical chemistry letters* 27; 4221-8.
- Hakemi Vala M, Hallajzadeh M, Hashemi A, Goudarzi H, Tarhani M, Sattarzadeh Tabrizi M, *et al.* (2014). Detection of Ambler class A, B and D β -lactamses among *Pseudomonas aeruginosa* and *Acinetobacter baumannii* clinical isolats from burn patients.
- Haryanti L. Pudjiadi A. H., Irfan E.K.B., Tayeb A., Amir., & Hegar B. (2013). Prevalens dan Faktor Risiko Infeksi Luka Operasi Pasca-Bedah. *Sari Pediatri*. Vol. 15 (4):207-212.
- Helen W. B, *et al.*, (2009). Bad Bugs, No Drugs: No ESKAPE! *An Update from The Infectious Diseases Society of America*. IDSA Report on Development Pipeline, 48.
- Juayang AC, Lim JPT, Bonifacio AFV, *et al.* (2017). Five-Year antimicrobial susceptibility of *P. aeruginosa* from a local tertiary hospital in Bacolod City, Philippines. *Tropical medicine and infectious disease*. 2-28.
- Karoma L. (2015). Plasmid Bakteri
- Khan ZA, Siddiqui MF, Park S. (2019). Current and emerging methods of antibiotic susceptibility testing. *Diagnostic* 9: 49.
- Kipnis E, SawaT, Wiener-Kronis J. (2006). Targeting mechanism of *Pseudomonas aeruginosa* pathogenesis. *Medicine et maladies infectieuses* 36: 78-91.
- Latifah R. (2014). Deteksi Enzim Karbapenemase dan Gen Pengkodennya pada Isolat *P. aeruginosa* dan *Acinetobacter baumannii* Resisten Karbapenem di ICU-RSUPN Cipto Mangunkusumo Tahun 2011 (Tesis). FK-UI, Jakarta.
- Lyczak JB, Cannon CL, Pier GB. (2000). Establishment of *P. aeruginosa* infection: lessons from a versatile opportunist. *Microbes aeruginosa infection*: 2: 1051-60.

- Mandell D. & Bennets. (2010). *Molecular Mechanisms of Antibiotic Resistance In Bacteria*. Principles and Practice of Infectious Diseases (279-345).
- Mohamed H. A. *et al.*, (2014). Molecular Characterization of Carbapenem-Insensitive *Acinetobacter baumannii* in Egypt, International Journal of Infectious Diseases 22(49-54).
- Murray P., (2013). Carbapenem-Resistant *Enterobacteriaceae*: What Has Happened, and what is Being done. *Clinical Microbiology Laboratories, University of Maryland Medical Center, Washington*.
- Navneet B., Sridaran D., Sahay D. & Belwali M.R.S., (2002). A Preliminary Study on Metallo β -Lactamase Producing *Pseudomonas aeruginosa* In hospitalized Patients. Indian J Med. Res; 22: 264-7.
- Nele B., Dirk V., and Stijn B., (2011). The Rising Problem of Antimicrobial Resistance in The Intensive Care Unit. *Annals of Intensive Care*, 1:47.
- Pappas G, Saplaoura K, Falagas ME.(2009). Current treatment of pseudomonal infection in the elderly. *Drugs & aging* 26: 363-79.
- Paterson D. L., (2005). *Resistance in Gram-Negative Bacteria: Enterobacteriaceae*. Pennsylvania: Elsevier.
- Paterson DL, Bonomo RA. (2005). Extended-Spectrum β -Lactamases: a clinical Update. *Clinical microbiology Reviews* 18: 657-86.
- Philip, S. B. (2012). *Multidrug-Resistant Organisms and Antibiotic Management*, Surgical.theclinics.com, 345-391, Elsevier Inc.
- Prihatini, Aryati, Hetty. (2007). Identifikasi Cepat Mikroorganisme Menggunakan Alat Vitek-2. *Indonesia n Journal of Clinical Pathology and Medical Laboratory* 13, : No.3 : 129-32.
- Queenan AM, Bush K. (2007). Carbapenemases: the versatile β -Lactamases. *Clinical microbiology reviews* 20: 440-58.
- Rashid A, Chowdhury A, Rahman SH, *et al.* (2007). Infections by *P. aeruginosa* and antibiotic resistance pattern of the isolat from Dhaka Medical College Hospital. *Bangladesh Journal of Medical Microbiology* 1 : 48-51.
- Rolsma S., Frank D.W., and Barbieri J.T. (2015). *P. aeruginosa* toxins. The Comprehensive Sourcebook of Bacterial Protein Toxins,133-160.

- Rouhi S, Ramazanzadeh R. (2018). Prevalence of blaOxacilinase-23 and blaOxacilinase-24/40-type Carbapenemases in *P. aeruginosa* Species Isolatd From Patients With Nosocomial and Non-nosocomial Infections in the West of Iran. *Iranian journal of pathology* 13: 348
- Ruis-Roldán L, Bellès A, Bueno J, *et al.* (2018). *P. aeruginosa* isolats from Spanish children: accurrence in faecal samples, antimicrobial resistancec, virulence, and molecular typing. *Biomed research international* 2018.
- Rusli., (2018). Struktur, Bentuk , dan penggolongan Bakteri.
- Rustini, Istiqamah S, Armin F. (2016). Penentuan multidrug resisten Pseudomonas aeruginosa (MDRPA) yang berasal dari sampel klinis pasien RSUD Dr. M. Djamil Padang. Prosiding Rakernas dan Pertemuan Ilmiah Tahunan Ikatan Apoteker Indonesia;2016 september 26'Yogyakarta. Indonesia.
- Sadikot RT, Blackwell TS, Christmas JW, *et al.* (2005). Pathogen-host interactions in *P. aeruginosa* Pneumonia. *American Journal of respiratory and critical care medicine* 171: 1209-23.
- Sanjaya IGNAP, Fatmawati NND, Hendrayana MA. PREVALENSI ISOLAT KLINIS *P. aeruginosa* pneumonia. *American journal of respiratory and critical care medicine* 171 : 1209-23.
- Santajit S, Indrawattana N. (2016). Mechanisme of antimicrobial resistance in ESKAPE pathogens. *Biomed research International* 2016.
- Shacheraghi F., Shakibaie M.R., Noveiri H. (2010). Molecular identification of ESBL Genes *bla*_{GES-1}, *bla*_{VEB-1}, *bla*_{CTX-M}, *bla*_{OXA-1}, *bla*_{OXA-4}, *bla*_{OXA-10} and *bla*_{PER-1} in *P. aeruginosa* Strains Isolatd from burn Patients by PCR, RFL and Sequencing and Technology International Academy of Science, Engineering and Technology International Journal of Bioengineering and Life Science Vol:4, No:1, 2010.p.114-117.
- Shanthi M, Sekar U, Kamalanathan A, Sekar B. (2014). Detection of New Delhi metallo beta lactamase-1 (NDM-1) carpanemase in *P. aeruginosa* in a singlr centre in southern India.
- Shen J, Pan Y, Fang Y. (2015). Role of the outer membrane protein OprD2 in carbapenem-resistance mechanisms of *P. aeruginosa*. *Plos one* 10: e0139995.

- Sitová M, Röderová M, Dendis M, *et al.* (2015). Application of molecular diagnostics in primary detection of ESBL directly from clinical specimens. *Microbial Drug Resistance* 21: 353-7.
- Soleha TU. (2015). Uji kepekaan terhadap antibiotik. *Juke Unila* 5: 119-23.
- Sony I, Potty V. (2017). Biochemical identification of protease producing bacterial isolats from food industries by vitek-2 compact system. *Int J. Curr. Microbiol.appl.sci* 6:840-51.
- Strateva T, Yordanov D. (2009). *P. aeruginosa*-a phenomom of bacterial resistance. *Journal of medical microbiology* 58: 1133-48.
- Todar K. (2012). *P. aeruginosa*. Todar;s Online Texbook of Bacteriology. Madison, Wisconsin.
- Uddhav S, Sivagurunathan M. (2016). Antibiotic susceptbility testing: A review on current practices. *Int J Pharm* 6: 11-7.
- Ullah W., Qasim M., Rahman H., Jie Y., Muhammad N. (2017). Beta-Lactamase-Producing *P. aeruginosa*: Phenotypic Characteristics and Molecular Identification of Virulence Genes. *Journal of Chines Medical Association* 80(2017): 174-177.
- Wu M. and Li X. (2015). *Klebsiella pneumonia* and *P. aeruginosa*. *Molecular Medical Micribiology*. DOI: 10.1016/B978-0-12-397169-2.00087-1.
- Wu W., Jin Y. and Jis. (2015). *P. aeruginosa*. *Molecular Medical Microbiology*. Doi:10-106/B978-0-12-397169-2.00041-X.
- Yu-Chi L., *et al.*, (2009). Differences in Carbapenem Resistance Genes Among *Acinetobacter baumannii*, *Acinetobacter genospecies* 3 and *Acinetobacter genospecies* 13TU in Taiwan. *International Journal of Antimicrobia Agen*: (439-443).
- Zao W-H, Hu Z-Q. (2010). B-Lactamases identified in clinical isolats of *P. aeruginosa*. *Clitical reviews in microbiology* 36: 245-58.

LAMPIRAN

Lampiran. 1 Rekomendasi Persetujuan Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,M.Med.PHD, SpGK. TELP. 081241850858. 0411 5780103. Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK
 Nomor : 174/UN4.6.4.5.31/ PP36/ 2023
 Tanggal: 15 Maret 2023


Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

| | | | |
|---------------------------------------|---|--|---------------------------|
| No Protokol | UH23030163 | No Sponsor | |
| Peneliti Utama | Fenti A. Tupanwael | Sponsor | |
| Judul Peneliti | Deteksi Pseudomonas Aeruginosa yang memproduksi VIM (PA-VIM) Pada Kultur udara ruang Sebelum dan sesudah dibersihkan pada ruang Perawatan ICU, Operasi, Luka bakar IGD dan CSSD serta Isolat dari Pasien di RS Wahiddin Sudirohusodo Makassar | | |
| No Versi Protokol | 1 | Tanggal Versi | 7 Maret 2023 |
| No Versi PSP | | Tanggal Versi | |
| Tempat Penelitian | RSUP Dr. Wahidin Sudirohusodo Makassar | | |
| Jenis Review | <input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal | Masa Berlaku | Frekuensi review lanjutan |
| | | 15 Maret 2023 sampai 15 Maret 2024 | |
| Ketua KEP Universitas Hasanuddin | Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K) | Tanda tangan | |
| Sekretaris KEP Universitas Hasanuddin | Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K) | Tanda tangan | |


Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran. 2 Gambar penelitian dan Hasil Elektroforesis




Gambar 1. Hasil Ekstraksi DNA




Gambar 2. Elektroforesis



Gambar 3. Proses Running PCR




Gambar 4. Hasil PCR Primer 16SrDNA Bakteri *P. aeruginosa*




Gambar 5. Hasil Elektroforesi produk PCR Isolat P. Aeruginosa 1-17 gen VIM (390 bp dan IMP (188 bp)




Gambar 6. Hasil Elektroforesi produk PCR Isolat P. Aeruginosa 18-25 gen VIM (390 bp dan IMP (188 bp)



Gambar 7. Hasil Elektroforesi produk PCR Isolat P. Aeruginosa 26-40 gen VIM (390 bp dan IMP (188 bp)



Hasil PCR Sampel dilusi Primer IMP



Hasil PCR Sampel dilusi Primer IMP

Lampiran. 3 Tabel Hasil Uji Sensitivitas Antibiotik dan PCR

| Kode Lab | AN | ATM | FEP | CAZ | CIP | CN | IMI | LVX | MEM | PIP-TZP | Hasil Multiplex PCR | |
|----------|----|-----|-----|-----|-----|----|-----|-----|-----|---------|---------------------|---------|
| | | | | | | | | | | | VIM | IMP |
| F.1 | S | S | R | I | R | S | R | R | R | I | Negatif | Negatif |
| F.2 | R | R | R | R | R | R | R | R | R | R | Negatif | Negatif |
| F.3 | R | R | R | S | R | S | R | R | R | S | Negatif | Negatif |
| F.4 | S | I | R | I | R | R | R | R | R | I | Negatif | Negatif |
| F.5 | S | I | R | R | S | S | S | S | S | I | Negatif | Negatif |
| F.6 | S | S | S | S | S | S | S | S | S | S | Negatif | Negatif |
| F.7 | S | S | S | S | S | S | S | S | S | S | Negatif | Negatif |
| F.8 | S | R | R | R | S | S | S | S | S | I | Negatif | Negatif |
| F.9 | S | R | R | S | S | S | S | S | S | S | Negatif | Negatif |
| F.10 | S | I | R | R | S | S | S | S | S | I | Negatif | Negatif |
| F.11 | S | S | S | S | S | S | R | S | S | S | Negatif | Negatif |
| F.12 | R | I | R | R | R | R | R | R | R | I | Negatif | Negatif |
| F.13 | S | S | R | I | S | S | R | I | R | S | Negatif | Negatif |
| F.14 | S | R | R | R | I | S | R | R | R | R | Negatif | Negatif |
| F.15 | I | I | R | R | R | R | R | R | R | S | Negatif | Negatif |
| F.16 | I | I | R | R | R | R | R | R | R | S | Negatif | Negatif |
| F.17 | R | R | R | R | R | R | R | R | R | R | Negatif | Negatif |
| F.18 | R | R | R | R | R | R | R | R | R | R | Negatif | Negatif |
| F.19 | S | S | S | S | R | R | R | R | R | I | Negatif | Negatif |
| F.20 | S | R | R | S | R | S | R | R | R | I | Negatif | Negatif |
| F.21 | S | R | R | S | S | S | S | S | R | I | Negatif | Negatif |
| F.22 | S | I | R | R | S | S | S | S | R | R | Negatif | Negatif |
| F.23 | S | S | S | S | S | S | S | S | S | S | Negatif | Negatif |
| F.24 | S | S | S | S | S | S | S | S | S | S | Negatif | Negatif |
| F.25 | S | S | S | S | S | S | S | S | S | S | Negatif | Negatif |
| F.26 | S | S | S | S | S | S | S | S | S | S | Negatif | Negatif |
| F.27 | S | S | S | S | S | S | S | S | S | S | Negatif | Negatif |
| F.28 | S | I | S | S | S | S | S | S | S | S | Negatif | Negatif |
| F.29 | S | S | S | S | S | S | S | S | S | S | Negatif | Negatif |
| F.30 | S | I | S | S | S | S | S | S | S | S | Negatif | Negatif |
| F.31 | S | S | S | S | S | S | S | S | S | S | Negatif | Negatif |
| F.32 | S | I | R | R | R | - | S | R | S | R | Negatif | Positif |
| F.33 | S | S | S | S | S | S | S | S | S | S | Negatif | Negatif |
| F.34 | S | R | S | S | S | S | S | S | S | S | Negatif | Positif |
| F.35 | S | S | S | S | R | R | S | - | S | S | Negatif | Negatif |
| F.36 | S | I | S | S | I | S | S | R | S | S | Negatif | Negatif |
| F.37 | S | R | R | S | S | S | S | S | S | S | Negatif | Negatif |
| F.38 | S | R | S | S | S | S | S | S | S | S | Negatif | Negatif |
| F.39 | S | R | S | I | R | S | S | R | S | S | Negatif | Negatif |
| F.40 | S | I | S | S | S | S | S | R | S | S | Negatif | Negatif |

